Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study
Objectives The clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-09-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605231198413 |
| _version_ | 1797678099657129984 |
|---|---|
| author | Randa Farah Hussam Al-Hawari Asma Albtoush Amani Nofal Tala Basheer Hyasat Raghed Abdel Hay Abu Jabeh Lojayn Tareq Suboh Ahmad A. Toubasi Tareq Fatah Eqrai Mohammad Abufaraj |
| author_facet | Randa Farah Hussam Al-Hawari Asma Albtoush Amani Nofal Tala Basheer Hyasat Raghed Abdel Hay Abu Jabeh Lojayn Tareq Suboh Ahmad A. Toubasi Tareq Fatah Eqrai Mohammad Abufaraj |
| author_sort | Randa Farah |
| collection | DOAJ |
| description | Objectives The clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with COVID-19 infection who had T2DM. Methods In this cross-sectional study, we included adult patients with T2DM who attended an endocrinology clinic and underwent testing for COVID-19 infection. Results Among 1039 included patients, the mean age was 59.5 ± 11.0 years and 429 (41.3%) were men. Overall, 87.1% of patients had received COVID-19 vaccination and 32.3% had confirmed COVID-19 infection. The COVID-19-related mortality was 3.0% and rate of post-COVID-19 lung fibrosis was 19.1%. Vaccination was associated with lower COVID-19-related mortality (odds ratio [OR]: 0.03, 95% confidence interval [CI]: 0.0–0.3) and post-COVID-19 lung fibrosis risk (OR: 0.3, 95% CI: 0.1–0.9). Conclusion Patients with T2DM exhibited a high prevalence of COVID-19 infection and associated mortality. However, COVID-19 vaccines were beneficial in reducing the risks of COVID-19-related mortality and post-infection lung fibrosis in these patients. COVID-19 vaccines and boosters are recommended for patients with T2DM. Further studies involving larger study populations are necessary to validate these findings. |
| first_indexed | 2024-03-11T22:54:46Z |
| format | Article |
| id | doaj.art-82c8aff4f0314fbb8bf2d986cd3ae5a2 |
| institution | Directory Open Access Journal |
| issn | 1473-2300 |
| language | English |
| last_indexed | 2024-03-11T22:54:46Z |
| publishDate | 2023-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-82c8aff4f0314fbb8bf2d986cd3ae5a22023-09-21T19:03:21ZengSAGE PublishingJournal of International Medical Research1473-23002023-09-015110.1177/03000605231198413Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional studyRanda FarahHussam Al-HawariAsma AlbtoushAmani NofalTala Basheer HyasatRaghed Abdel Hay Abu JabehLojayn Tareq SubohAhmad A. ToubasiTareq Fatah EqraiMohammad AbufarajObjectives The clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with COVID-19 infection who had T2DM. Methods In this cross-sectional study, we included adult patients with T2DM who attended an endocrinology clinic and underwent testing for COVID-19 infection. Results Among 1039 included patients, the mean age was 59.5 ± 11.0 years and 429 (41.3%) were men. Overall, 87.1% of patients had received COVID-19 vaccination and 32.3% had confirmed COVID-19 infection. The COVID-19-related mortality was 3.0% and rate of post-COVID-19 lung fibrosis was 19.1%. Vaccination was associated with lower COVID-19-related mortality (odds ratio [OR]: 0.03, 95% confidence interval [CI]: 0.0–0.3) and post-COVID-19 lung fibrosis risk (OR: 0.3, 95% CI: 0.1–0.9). Conclusion Patients with T2DM exhibited a high prevalence of COVID-19 infection and associated mortality. However, COVID-19 vaccines were beneficial in reducing the risks of COVID-19-related mortality and post-infection lung fibrosis in these patients. COVID-19 vaccines and boosters are recommended for patients with T2DM. Further studies involving larger study populations are necessary to validate these findings.https://doi.org/10.1177/03000605231198413 |
| spellingShingle | Randa Farah Hussam Al-Hawari Asma Albtoush Amani Nofal Tala Basheer Hyasat Raghed Abdel Hay Abu Jabeh Lojayn Tareq Suboh Ahmad A. Toubasi Tareq Fatah Eqrai Mohammad Abufaraj Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study Journal of International Medical Research |
| title | Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study |
| title_full | Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study |
| title_fullStr | Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study |
| title_full_unstemmed | Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study |
| title_short | Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study |
| title_sort | prevalence and risk factors of covid 19 infection mortality and post infection lung fibrosis in patients with type 2 diabetes a cross sectional study |
| url | https://doi.org/10.1177/03000605231198413 |
| work_keys_str_mv | AT randafarah prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT hussamalhawari prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT asmaalbtoush prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT amaninofal prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT talabasheerhyasat prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT raghedabdelhayabujabeh prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT lojayntareqsuboh prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT ahmadatoubasi prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT tareqfataheqrai prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy AT mohammadabufaraj prevalenceandriskfactorsofcovid19infectionmortalityandpostinfectionlungfibrosisinpatientswithtype2diabetesacrosssectionalstudy |